OncLive TV

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.

Nilofer S​aba Azad, MD, discusses future research efforts in colorectal cancer.

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

Allyson Ocean, ​MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.

Derek C. Galligan, MD, discusses transplant eligibility in determining subsequent treatment for patients with multiple myeloma.

Arun Azad, PhD, discusses the design of the ​phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.

Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.

Neal D. Shore, MD, FACS, discusses the design of the phase 3 HERO trial in patients with advanced prostate cancer.

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Lucia Masarova, MD, discusses future research ​efforts in myeloproliferative neoplasms.

Elisavet Paplomata, MD, discusses the role of tucatinib ​in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Nilofer S​aba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of tazemetostat in epithelioid sarcoma.

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.